Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder

NCT01363310 is registered in ClinicalTrials.gov with Physicians Research And Education Network as lead sponsor.

NCT NCT01363310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01363310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder
Lead sponsor
Physicians Research And Education Network
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2010
Completion date
February 28, 2013
Enrollment
250 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

depression with prominent agitation